Prostate Cancer International is
for 2011 by Great NonProfits
The key prostate cancer presentations today at the annual meeting of the American Society of Clinical Oncology (ASCO) were all given at a morning session on high-risk and advanced prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, enzalutamide, MDV3100 | 2 Comments »
Studies to be presented at the ASCO meeting next week suggest that: (a) high-dose ketoconazole has very limited activity in the treatment of men who have already been treated with abiraterone acetate; (b) men treated with either high-dose ketoconazole or abiraterone acetate (or both) can still respond to docetaxel-based chemotherapy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, chemotherapy, CRPC, ketoconazole, outcome, sequence | 1 Comment »
Acccording to an article on the Medscape web site today, the convicted “Lockerbie bomber,” Abdelbaset al Megrahi, finally died on Sunday, 2 years and 9 months after his release from a Scottish prison on compassionate grounds because he was close to dying of terminal prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, al Megrahi, survival | 9 Comments »
According to information on the web site of the National Institute for Clinical Excellence (NICE), revised draft guidance has been issued by NICE regarding the routine use of abiraterone acetate.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, access, NICE, UK | 1 Comment »
According to the abstract of a paper to be presented at the upcoming meeting of the American Society for Clinical Oncology in Chicago at the beginning of June, 24 weeks of treatment with neoadjuvant abiraterone acetate + prednisone + an LHRH agonist appears to be able to eliminate visible risk of prostate cancer in post-surgical [...]
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment, Uncategorized | Tagged: abiraterone, dutasteride, enzalutamide, leuprolide, MDV3100, neoadjuvant, pre-surgical | 6 Comments »
According to recent articles in the media, the National Institute for Clinical Excellence (NICE) will shortly issue a recommendation that abiraterone is covered for routine use in the UK among men with chemotherapy-refractory, metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, NICE, UK | 2 Comments »
An article just published in Cancer Research this week suggests that adding the investigational agent enzalutamide (MDV3100) to abiraterone acetate and prednisone in men being treated for metastatic, castration-resistant prostate cancer (mCRPC) may be able to further delay disease progression among men showing signs of progression after initial treatment with abiraterone acetate.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, enzalutamide, mCRPC, MDV3100 | 2 Comments »
Here is a question that is on the minds of many physicians and patients on Planet Prostate Cancer today: Can treatment with abiraterone acetate or similar agents replace the continuous and/or the intermittent first-line use of LHRH-agonist–induced medical castration in patients with high-risk and advanced forms of prostate cancer?
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, enzalutamide, LHRH agonist, MDV3100 | 8 Comments »
We are now able to confirm that the full results of the Phase III trial of abiraterone acetate + placebo in the treatment of men with chemotherapy-naïve, metastatic, castration-resistant prostate cancer are being submitted for approval
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: abiraterone, castration-resistant, chemotherapy-naïve, medtaststic | 2 Comments »
It has been suggested that, after an initial “loading dose” for a period of time, abiraterone acetate could potentially be used to treat metastatic, castration-resistant prostate cancer (mCRPC) at a much lower daily maintenance dose than that currently approved.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, low-dose, maintenance | 10 Comments »
In an utterly unsurprising announcement from the UK, the National Institute for Clincial Excellence (NICE) has issued draft guidance in which it refuses to cover the proposed cost of abiraterone actetate.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, cost, NICE, UK, Zytiga | 6 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site